Native Nanovesicular Therapeutics
Native Nanovesicular Therapeutics
Program line 2 exploits the inherent anti-inflammatory and pro-regenerative activities of NVs for tissue repair and the treatment of chronic inflammatory conditions.
Our focus is on naturally secreted EVs from human primary mesenchymal stem cells (MSC), human platelets, and milk, as well as on artificially produced NVs (CDVs) and hybrid NVs. We determine the mechanisms, components, and parameters critical for the successful translation of bioactive NVs into clinical applications by:
- Developing robust and reproducible manufacturing processes with defined critical quality attributes for anti-inflammatory / pro-regenerative NVs from different sources.
- Determining therapeutically relevant modes of action to guide NVTx development.
- Identifying co-factors and scaffolds for the optimization of NVTx.
- Profiling preclinically in cellular and animal models to stratify clinical NVTx candidates.
